Eby defends investigation 
Ferries brace for big summer
Premier Eby heading to Asia
Vote final despite error
2 found dead in wildfire
CBC to stop paying bonuses
Overdose deaths fall 27%
Rollback on protections
Business ties deepen
Secession talk 'unhelpful'
Delivery driver steals $2.5M
Roaming revenue falls
Vees season ends in game 6
Leafs' ugly Game 4 loss
Vees heading to game 6
Foo Fighters at Singapore F1
Accuser rips defense lawyer
Max revives HBO name
Parents with children who suffer from migraine headaches may have a new treatment option thanks to a clinical research study being offered at Okanagan Clinical Trials.
“Migraine headaches can be difficult for anyone, but especially so for children,” Okanagan Clinical Trials general practitioner and principal investigator Dr. Colleen Maytham says. “Pediatric migraines can be so debilitating that they cause children to miss school or extracurricular activities. New treatment options are needed.”
The investigational study drug, Rimegepant, is a tablet for the acute treatment of migraines and is already approved for use in adults in the U.S., but not yet in Canada.?The participant must be 6-17 years of age and have a history of migraine attacks for more than six months, occurring one to eight times per month and lasting at least three hours or more in duration without treatment. Volunteers meeting these and other criteria will be asked to undergo a screening visit to determine eligibility.
Approximately 2,330 participants will need to be screened to enrol approximately 2,100 eligible participants.
Site staff will be in regular contact with participants, as well as their parents or guardians. All study drugs and study procedures will be provided to participants at no charge. Participants may also be reimbursed for their travel and other incidental expenses.
“I consistently hear positive feedback from volunteers participating in our clinical trials,” Okanagan Clinical Trials president Dr. Kim Christie says. “Being part of the study allows participants to feel like they have some semblance of control over their diagnosis, which can be empowering.”
For more information or to volunteer for the study, visit www.okanaganclinicaltrials.com or call Okanagan Clinical Trials at 250-862-8141.
This article is written by or on behalf of the sponsoring client and does not necessarily reflect the views of Castanet.
